As of 2026-09-11, the Relative Valuation of Alnylam Pharmaceuticals Inc (ALNY) is 112.88 USD. This relative valuation is based on P/E multiples. With the latest stock price at 247.51 USD, the upside of Alnylam Pharmaceuticals Inc based on Relative Valuation is -54.4%.
The range of the Relative Valuation is 101.26 - 155.78 USD.
| Range | Selected | |
| Trailing P/E multiples | 17.5x - 25.7x | 19.2x |
| Forward P/E multiples | 27.8x - 37.9x | 30.1x |
| Fair Price | 101.26 - 155.78 | 112.88 |
| Upside | -59.1% - -37.1% | -54.4% |
| Date | P/E |
| 2026-09-10 | 40.90 |
| 2026-09-09 | 42.63 |
| 2026-09-08 | 42.98 |
| 2026-09-04 | 43.97 |
| 2026-09-03 | 43.71 |
| 2026-09-02 | 44.18 |
| 2026-09-01 | 40.67 |
| 2026-08-31 | 39.77 |
| 2026-08-28 | 39.18 |
| 2026-08-27 | 39.09 |
| 2026-08-26 | 39.49 |
| 2026-08-25 | 39.67 |
| 2026-08-24 | 39.00 |
| 2026-08-21 | 39.03 |
| 2026-08-20 | 37.89 |
| 2026-08-19 | 40.09 |
| 2026-08-18 | 37.77 |
| 2026-08-17 | 37.11 |
| 2026-08-14 | 37.78 |
| 2026-08-13 | 37.53 |
| 2026-08-12 | 37.00 |
| 2026-08-11 | 36.55 |
| 2026-08-10 | 35.85 |
| 2026-08-07 | 36.22 |
| 2026-08-06 | 35.71 |
| 2026-08-05 | 37.79 |
| 2026-08-04 | 36.19 |
| 2026-08-03 | 36.41 |
| 2026-07-31 | 33.96 |
| 2026-07-30 | 33.95 |
| 2026-07-29 | 47.36 |
| 2026-07-28 | 47.66 |
| 2026-07-27 | 46.00 |
| 2026-07-24 | 44.91 |
| 2026-07-23 | 44.41 |
| 2026-07-22 | 44.12 |
| 2026-07-21 | 44.84 |
| 2026-07-20 | 45.06 |
| 2026-07-17 | 44.20 |
| 2026-07-16 | 46.79 |
| 2026-07-15 | 46.12 |
| 2026-07-14 | 46.47 |
| 2026-07-13 | 47.60 |
| 2026-07-10 | 49.37 |
| 2026-07-09 | 51.68 |
| 2026-07-08 | 53.45 |
| 2026-07-07 | 53.14 |
| 2026-07-06 | 51.73 |
| 2026-07-02 | 51.68 |
| 2026-07-01 | 49.85 |